Want to see FR:SIGHT full AI Analyst Report?
GenSight Biologics SA (SIGHT) Ratios
GenSight Biologics SA Ratios
FR:SIGHT's free cash flow for Q2 2026 was $-1.80M. For the 2026 fiscal year, FR:SIGHT's free cash flow was decreased by $-66.00K and operating cash flow was $-1.73M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.39 | 0.24 | 0.26 | 1.57 | 2.40 |
| Quick Ratio | 0.39 | 0.24 | 0.26 | 0.99 | 2.20 |
| Cash Ratio | 0.19 | 0.11 | 0.08 | 0.72 | 1.99 |
| Solvency Ratio | -0.35 | -0.34 | -0.58 | -0.64 | -0.68 |
| Operating Cash Flow Ratio | -0.74 | -0.57 | -0.98 | -2.31 | -0.77 |
| Short-Term Operating Cash Flow Coverage | -2.85 | -0.97 | -1.49 | -21.99 | -3.67 |
| Net Current Asset Value | $ -28.22M | $ -32.33M | $ -33.30M | $ -18.27M | $ 12.71M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.56 | 1.78 | 2.58 | 0.49 | 0.22 |
| Debt-to-Equity Ratio | -0.52 | -0.71 | -0.77 | -0.83 | 0.79 |
| Debt-to-Capital Ratio | -1.06 | -2.45 | -3.30 | -4.81 | 0.44 |
| Long-Term Debt-to-Capital Ratio | -0.59 | -0.21 | -0.20 | -1.53 | 0.26 |
| Financial Leverage Ratio | -0.33 | -0.40 | -0.30 | -1.70 | 3.54 |
| Debt Service Coverage Ratio | -2.63 | -0.99 | -1.10 | -6.40 | -3.73 |
| Interest Coverage Ratio | -11.86 | -10.18 | -9.42 | -10.50 | -12.99 |
| Debt to Market Cap | 0.81 | 0.70 | 0.98 | 0.07 | 0.04 |
| Interest Debt Per Share | 0.09 | 0.22 | 0.55 | 0.33 | 0.33 |
| Net Debt to EBITDA | -0.93 | -1.13 | -0.98 | -0.08 | 1.24 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 236.78% | 100.00% | 100.00% |
| EBIT Margin | -1170500.00% | -602.44% | -1954.54% | -1078.04% | -501.31% |
| EBITDA Margin | -1124000.00% | -562.10% | -1715.07% | -1036.95% | -483.72% |
| Operating Profit Margin | -1170500.00% | -602.40% | -2343.80% | -1078.04% | -533.09% |
| Pretax Profit Margin | -1204100.00% | -532.57% | -2069.53% | -1069.67% | -542.36% |
| Net Profit Margin | -1203600.00% | -533.37% | -2069.46% | -1069.87% | -542.40% |
| Continuous Operations Profit Margin | -1204600.00% | -533.37% | -2069.46% | -1069.87% | -542.40% |
| Net Income Per EBT | 99.96% | 100.15% | 100.00% | 100.02% | 100.01% |
| EBT Per EBIT | 102.87% | 88.41% | 88.30% | 99.22% | 101.74% |
| Return on Assets (ROA) | -145.78% | -130.17% | -287.12% | -106.49% | -50.52% |
| Return on Equity (ROE) | 48.26% | 52.01% | 85.50% | 180.80% | -178.97% |
| Return on Capital Employed (ROCE) | 265.24% | 133.31% | 183.79% | -246.35% | -81.75% |
| Return on Invested Capital (ROIC) | 1518.16% | -776.29% | -2430.02% | -202.76% | -70.64% |
| Return on Tangible Assets | -145.78% | -130.86% | -289.50% | -106.87% | -50.62% |
| Earnings Yield | -77.74% | -54.15% | -117.97% | -17.73% | -11.40% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 2625.00 | 1267.00 | 0.74 | 7.00 |
| Payables Turnover | 0.00 | 0.00 | -0.31 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 1733.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 2.81 | 0.63 | 1.14 | 2.07 |
| Asset Turnover | 0.00 | 0.24 | 0.14 | 0.10 | 0.09 |
| Working Capital Turnover Ratio | -0.00 | -0.15 | -0.24 | 0.13 | 0.18 |
| Cash Conversion Cycle | 575605.00 | 0.14 | 1187.12 | 493.36 | 52.16 |
| Days of Sales Outstanding | 575605.00 | 0.14 | 0.29 | 493.36 | 52.16 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | -1186.62 | 0.00 | 0.00 |
| Operating Cycle | 575605.00 | 0.14 | 0.50 | 493.36 | 52.16 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.06 | -0.14 | -0.51 | -0.73 | -0.38 |
| Free Cash Flow Per Share | -0.06 | -0.14 | -0.51 | -0.73 | -0.38 |
| Dividend Paid and CapEx Coverage Ratio | -2344.50 | -12937.00 | -2466.30 | -133.94 | -535.59 |
| Capital Expenditure Coverage Ratio | -2344.50 | -12937.00 | -2466.30 | -133.94 | -535.59 |
| Operating Cash Flow Coverage Ratio | -0.73 | -0.68 | -1.05 | -2.67 | -1.36 |
| Operating Cash Flow to Sales Ratio | -9378.00 | -4.93 | -19.47 | -13.07 | -3.25 |
| Free Cash Flow Yield | -60.60% | -50.04% | -111.01% | -21.83% | -6.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.29 | -1.80 | -0.85 | -5.64 | -8.77 |
| Price-to-Sales (P/S) Ratio | 15482.52 | 9.85 | 17.54 | 60.33 | 47.58 |
| Price-to-Book (P/B) Ratio | -0.62 | -0.96 | -0.72 | -10.19 | 15.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.65 | -2.00 | -0.90 | -4.58 | -14.62 |
| Price-to-Operating Cash Flow Ratio | -1.65 | -2.00 | -0.90 | -4.61 | -14.65 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.02 | 0.08 | 1.18 | 0.25 |
| Enterprise Value Multiple | -2.31 | -2.88 | -2.01 | -5.89 | -8.59 |
| Enterprise Value | 25.93M | 42.50M | 43.63M | 157.80M | 219.32M |
| EV to EBITDA | -2.31 | -2.88 | -2.01 | -5.89 | -8.59 |
| EV to Sales | 25930.52 | 16.19 | 34.43 | 61.12 | 41.57 |
| EV to Free Cash Flow | -2.76 | -3.29 | -1.77 | -4.64 | -12.77 |
| EV to Operating Cash Flow | -2.77 | -3.29 | -1.77 | -4.68 | -12.80 |
| Tangible Book Value Per Share | -0.17 | -0.28 | -0.64 | -0.33 | 0.35 |
| Shareholders’ Equity Per Share | -0.17 | -0.28 | -0.63 | -0.33 | 0.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.03 | 0.03 | 0.06 | 0.12 |
| Net Income Per Share | -0.08 | -0.15 | -0.54 | -0.60 | -0.63 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.03 | 0.88 | 1.06 | 0.99 | 1.08 |
| Research & Development to Revenue | 6440.00 | 4.71 | 15.28 | 7.33 | 4.27 |
| SG&A to Revenue | 2628.00 | 2.31 | 5.13 | 3.10 | 1.08 |
| Stock-Based Compensation to Revenue | 391.00 | 0.30 | 0.46 | -1.30 | 0.92 |
| Income Quality | 0.78 | 0.92 | 0.94 | 1.22 | 0.60 |
Currency in EUR